This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

ISPE Drug Shortage Initiative Issues Survey In Support Of Global Efforts To Understand Drug Shortages

TAMPA, Fla., Feb. 14, 2013 /PRNewswire-USNewswire/ --  ISPE, the International Society for Pharmaceutical Engineering, announced today it will conduct a global survey on drug shortages that will be sent directly to its international Membership in mid-February. As a not-for-profit association with both industry and regulator Members in 90 countries, ISPE is uniquely positioned to facilitate communication between the different sectors of the pharmaceutical industry and global health authorities as they seek to address this complex problem. The survey goal is to leverage ISPE Members' expertise to gather data on the technical, scientific, manufacturing, quality and compliance issues that have resulted in drug shortages. Preliminary results are expected in June 2013.

(Logo: http://photos.prnewswire.com/prnh/20120912/DC73253LOGO)

"The prevention of drug shortages is critically important to global health," said Nancy S. Berg, ISPE President and CEO. "Any effort to effectively address the complex and multi-faceted issues contributing to drug shortages requires close technical collaboration and clear communication between the pharmaceutical industry and global health authorities. ISPE is committed to supporting efforts to uncover the root causes of drug shortages, and we believe this survey is a critical first step."

The survey was developed by ISPE's Drug Shortage Initiative, led by a task force of industry leaders with review and input by leading global health authorities and related organizations. By design, the task force has limited the scope of this survey to the technical, scientific, manufacturing, quality and compliance issues that have resulted in drug shortages. Survey responses will be completely anonymous, and all data will be tabulated by a third-party firm.

ISPE's goal in collecting this survey data is to provide the pharmaceutical industry and health authorities with much-needed scientific data to support the development of risk-based approaches, using modern quality systems, to mitigate and prevent drug shortages. ISPE also plans to leverage its international network to lead collaboration between regulators and industry regarding drug shortages through meetings, conferences and industry groups like the International Leadership Forum.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs